PJSC “Scientific and Production Center ”Borshchahivsky Chemical and Pharmaceutical Plant” (BCPP) increased its net profit by 2.96% to UAH 281.788 million in 2025.
According to the company’s website, BCHP increased its production of pharmaceutical products by 16% in 2025, reaching 37.4 million packages worth UAH 2.481 billion.
According to the company, total sales of finished products and goods in 2025 amounted to 43.8 million packages, which is 6.9% more than in 2024.
In addition, the company reported that in 2025, BHFZ exported products worth UAH 307 million, accounting for 13.7% of total sales.
BHFZ exported its products to countries in Eastern and Western Europe, the Baltic states, the Caucasus, Central Asia, and other distant foreign markets, as well as to countries within the CIS.
Net sales revenue for 2025 amounted to UAH 2.259 billion, which is 7.9% more than the previous year.
BHFZ forecasts an 18% increase in net sales revenue for 2026 compared to 2025. Annual growth during 2027–2028 is expected to be 13%
The company also reported that in 2025, BHFZ was developing 12 drugs in four dosage forms; one clinical trial was completed, and preparations are underway for two more clinical trials.
Additionally, BHFZ completed the registration process for one drug in Ukraine and seven abroad.
In total, in 2025, BHFZ registered four finished pharmaceutical products and five APIs. One drug was submitted for registration in CIS countries, and four drugs were registered in countries outside the CIS.
The company noted that BHFZ is striving to maintain retail prices at pre-war levels and has adjusted its product portfolio to account for wartime conditions; it has also managed to maintain the continuity of supply chains.
In addition, the BHFZ Group has created the necessary reserve of production stocks and raw materials, which is constantly updated, to ensure uninterrupted production throughout 2026.
As reported, BHFZ is seeking to recover UAH 50.7 million in damages from the Russian Federation for the destruction and damage of property resulting from armed aggression, specifically the destruction and damage of property caused by a rocket attack on July 31, 2025.
The court accepted the statement of claim for consideration and opened proceedings in the case. As part of the investigation, an expert assessment was conducted, according to which the amount of direct (actual) damages caused to BHFZ as a result of the loss, destruction, or damage to property (fixed assets and inventory according to the lists) in connection with the armed aggression of the Russian Federation (as a result of the explosion and fire on July 31, 2025) amounts to UAH 50,760,894, which, at the NBU exchange rate as of the date of the assessment (July 31, 2025), is equivalent to $1,215,358.
Currently, the shareholders of BHFZ are the pharmaceutical company PJSC “Pharmaceutical Firm ‘Darnitsa’ (Kyiv), which owns 31.8% of BHFZ’s shares; other shareholders include ”Beldor Group“ (21.26%) and ”Lenik Group” (20.32%) .
The ultimate beneficiaries of BHFZ are the beneficiaries of the pharmaceutical company “Darnitsa”: Gleb Zagoriy, Yevgen Sova, Tetiana Artemenko, Mykola Bezpalko, and Oleg Goloborodko.
